Overview


According to FutureWise analysis, the market for Rabies Antiserum is expected to grow with a CAGR of 3.3% over the forecast period 2024-2032, and reach a market value of US$ 1.6 Billion by 2031. 

Rabies antiserum, also known as anti-rabies serum (ARS), is a specialized medical product used in the post-exposure treatment of individuals potentially exposed to the rabies virus. Rabies is a deadly viral infection that affects the central nervous system, and once symptoms appear, it is almost always fatal. As a result, immediate and appropriate medical intervention is crucial after a potential exposure to the virus.

Rabies antiserum is derived from the blood of animals, typically horses or other mammals, hyperimmunized with inactivated rabies virus. This process stimulates the animals' immune systems to produce antibodies against the rabies virus. The blood is then collected, and the serum containing these antibodies is purified and processed for therapeutic use in humans. When administered, the rabies antiserum provides immediate passive immunity against the rabies virus. This means it contains pre-formed antibodies that can immediately neutralize the virus, offering temporary protection while the recipient's immune system mounts a response. The antiserum provides immediate protection, while the rabies vaccine stimulates the recipient's immune system to produce antibodies against the virus for long-term immunity. Rabies antiserum is primarily indicated for individuals who have sustained potentially severe exposures to the rabies virus, such as bites or scratches from animals suspected to be rabid. This treatment is administered as part of a comprehensive post-exposure prophylaxis protocol recommended by healthcare authorities.

FutureWise Market Research has published a report that provides an insightful analysis of Rabies Antiserum Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Rabies Antiserum Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • CSL Behring
  • Sanofi Pasteur
  • Grifols S.A.
  • Bharat Serum and Vaccines Ltd.
  • Novartis AG
  • Kedrion Biopharma Inc.
  • Biogenesis Bago SA
  • MassBiologics
  • Serum Institute of India Ltd.
  • Green Cross Corp.
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Shanghai Institute of Biological Products Co. Ltd.
  • CNBG (China National Biotec Group) Co. Ltd.
  • Harbin Pharmaceutical Group Co. Ltd.
  • Beijing Tiantan Biological Products Co. Ltd

(Note: The list of the major players will be updated with the latest market scenario and trends)

Regions with a higher incidence of rabies cases, particularly in areas where rabies is endemic in wildlife, drive the demand for rabies antiserum for post-exposure prevention and treatment. Efforts to educate communities and healthcare professionals about the importance of timely post-exposure treatment for potential rabies exposures contribute to increased demand for rabies antiserum. Government-sponsored vaccination programs for pets and wildlife and public health initiatives can raise awareness of rabies and the need for post-exposure prophylaxis. Travelers to regions with higher rabies prevalence, mainly tourists engaging in outdoor activities or animal-related adventures, may drive the demand for rabies antiserum as a precautionary measure.

However, there are significant restraints for the market. Availability and access to rabies antiserum may be limited in certain developing regions due to inadequate healthcare infrastructure, distribution challenges, and economic constraints. Developing and promoting rabies pre-exposure vaccination, which provides longer-term protection, may reduce the demand for post-exposure treatment with antiserum. Stringent regulatory requirements and safety concerns regarding the production and quality of rabies antiserum can pose challenges for manufacturers, potentially impacting market entry. The cost of rabies antiserum and associated treatment can be a significant factor, particularly in regions with limited healthcare resources, or individuals may face financial constraints and hinder the market.

By Product Type

  • Human Rabies Immunoglobulin (HRIG)
  • Equine Rabies Immunoglobulin (ERIG)

By Application

  • Pre-Exposure Prophylaxis (PrEP)
  • Post-Exposure Prophylaxis (PEP)

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • Europe
  • North America
  • Asia Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to the widespread occurrence of rabies in the area and the accessibility of advanced treatment alternatives, the market exhibits significant growth potential. Conversely, the Asia-Pacific region is positioned for notable expansion in the projected period. This is attributed to the high prevalence of rabies, heightened awareness about the disease, and governmental efforts aimed at disease management. Additionally, there is a rising demand for top-tier healthcare services in the region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Rabies Antiserum Market By Product Type, By Application, By Distribution Channel, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1. Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2. Primary Data
              1.2.1. Key Data from Primary Sources
        3. Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Rabies Antiserum Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Rabies Antiserum Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Rabies Antiserum Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Rabies Antiserum Market, By Product Type Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Human Rabies Immunoglobulin (HRIG)
        2. Equine Rabies Immunoglobulin (ERIG)

  • 8.  Rabies Antiserum Market, By Application Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Pre-Exposure Prophylaxis (PrEP)
        2. Post-Exposure Prophylaxis (PEP)

  • 9.  Rabies Antiserum Market, By Distribution Channel Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies

  • 10.  North America Rabies Antiserum Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 11.  Latin America Rabies Antiserum Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 12.  Europe Rabies Antiserum Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 13.  Asia Pacific Rabies Antiserum Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032

  • 14.  Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 15.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 16.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)
    •   1. CSL Behring
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. Sanofi Pasteur
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. Grifols S.A.
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. Bharat Serum and Vaccines Ltd.
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. Novartis AG
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. Kedrion Biopharma Inc.
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. Biogenesis Bago SA
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. MassBiologics
           8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview
        9. Serum Institute of India Ltd.
           9.1. Company Overview
           9.2. Product Portfolio
           9.3. SWOT Analysis
           9.4. Financial Overview
           9.5. Strategic Overview
        10. Green Cross Corp.
           10.1. Company Overview
           10.2. Product Portfolio
           10.3. SWOT Analysis
           10.4. Financial Overview
           10.5. Strategic Overview
        11. Haffkine Bio-Pharmaceutical Corporation Ltd.
           11.1. Company Overview
           11.2. Product Portfolio
           11.3. SWOT Analysis
           11.4. Financial Overview
           11.5. Strategic Overview
        12. Shanghai Institute of Biological Products Co. Ltd.
           12.1. Company Overview
           12.2. Product Portfolio
           12.3. SWOT Analysis
           12.4. Financial Overview
           12.5. Strategic Overview
        13. CNBG (China National Biotec Group) Co. Ltd.
           13.1. Company Overview
           13.2. Product Portfolio
           13.3. SWOT Analysis
           13.4. Financial Overview
           13.5. Strategic Overview
        14. Harbin Pharmaceutical Group Co. Ltd.
           14.1. Company Overview
           14.2. Product Portfolio
           14.3. SWOT Analysis
           14.4. Financial Overview
           14.5. Strategic Overview
        15. Beijing Tiantan Biological Products Co. Ltd.
           15.1. Company Overview
           15.2. Product Portfolio
           15.3. SWOT Analysis
           15.4. Financial Overview
           15.5. Strategic Overview

  • 17.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
            administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.  FutureWise SME Key Takeaway Points for Client
    •   

Partner

Our Clients